

TYSABRI (natalizumab)

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with **TYSABRI**. Please follow the advice in this form to ensure that you are fully informed of, and understand the continued risk of **PML** (progressive multifocal leukoencephalopathy) for up to 6 months following discontinuation of **TYSABRI**.

Before starting treatment with **TYSABRI** you should have received an Alert Card from your doctor. This Alert Card should be kept for 6 months after discontinuation of treatment as it has important information about **PML** for your reference.

PML is a rare brain infection that has occurred in patients who have been given **TYSABRI**, and which may lead to severe disability or death. **PML** has been reported up to 6 months after discontinuation of **TYSABRI**.

Signs include:

- Changes in mental ability and concentration
- Behavioural changes
- Weakness on one side of the body
- Vision problems
- New neurological symptoms that are unusual for you

Symptoms of **PML** may be similar to an **MS** relapse. Therefore, if you believe your **MS** is getting worse or if you notice any new symptoms for up to 6 months after stopping **TYSABRI** treatment, it is very important that you speak to your doctor as soon as possible.

During the 6 months following treatment discontinuation of **TYSABRI**, your doctor will monitor you and will decide when you should receive **MRI** imaging. In general, you will continue to receive 3-6 month **MRI** imaging if you have either of the following combination of **PML** risk factors:

- You have antibodies to the **JC** virus, have taken **TYSABRI** for more than 2 years and previously taken an immunosuppressant (a medicine that reduces the activity of your body's immune system) at any time before starting **TYSABRI**
- You have never taken an immunosuppressant therapy before starting **TYSABRI**, but have taken **TYSABRI** for more than 2 years and have a high anti-**JCV** antibody index (increased amount of antibody in your blood)

If you do not fall into one of the above groups, then you will continue to receive routine **MRI**s as prescribed by your doctor.

Should you have any questions about the above information, please ask your doctor.

If you do not have the Alert Card that you received when starting **TYSABRI**, then please ask your doctor for a new card. You should keep the Alert Card with you to remind you of the important safety information, in particular any symptoms you may develop which could possibly indicate **PML**, if appropriate, you should show the Alert Card to your partner or caregiver.

Patient's Name (print)

Patient's Signature

Date

Doctor's Name (print)

Doctor's Signature

Date

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in the patient leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for **MHRA Yellow Card** in the Google Play or Apple App Store, or if in Ireland, via **HPRA Pharmacovigilance**, Earlsfort Terrace, IRL- Dublin 2; Tel: +353 16764971; Fax: +353 16762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.